Lipid Disorder Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Lipid Disorder Treatment Market is Segmented by Indication (Hypercholesterolemia, Dysbetalipoproteinemia, Familial Combined Hyperlipidemia, Others), Distribution Channel, and Geography

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 7.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The major factors attributing to the growth of the lipid disorder treatment market are the growing prevalence of lifestyle diseases like obesity and increasing smoking and alcohol consumption. Lifestyle diseases are conditions associated with the way people live. They include atherosclerosis, heart disease, stroke, obesity, and type 2 diabetes. As per the World Health Organization (WHO), in 2016, more than 1.9 billion adults, 18 years and older, were overweight. Of these over 650 million were obese, However, in 2018, 40 million children under the age of 5 were overweight or obese. 

Furthermore, the increasing growth of familial combined hyperlipidemia incidence rate also plays a major role in the growth of the market. However, the side effects of the medication involved in the treatment are the restraint to the growth of the market.

Scope of the Report

As per the scope of the report, lipid disorders comprise a broad spectrum of conditions where the blood lipid levels are affected. Generally, it is associated with an increase in the blood lipid levels. 

By Indication
Familial Combined Hyperlipidemia
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Familial Combined Hyperlipidemia Incidence Rate is Expected to Show a High Growth

Familial combined hyperlipidemia is the most common congenital disorder that increases blood fats. It causes high cholesterol and high blood triglycerides which can cause early heart attacks. The rate of incidence of this disease is high in adults, and the treatment market for the disease is profitable for the key players involved in the manufacturing of the drugs. As this condition is common, the drugs for this disease have maximum sales and generates maximum revenue. 

Statins are the class of drugs that are used to treat familial combined hyperlipidemia, the same is used to treat related conditions like obesity. Therefore as the incidence of obesity increases the market growth rate of this segment also increases. 

As per the National Organization for Rare Disorders(NORD), 1 in 220 people have familial combined hyperlipidemia and these statistics prove that the increasing patient pool is directly proportional to the market growth.


North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall lipid disorder treatment market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of obesity and other lifestyle disorders in the region, established healthcare infrastructure, are some of the key factors accountable for its large share in the market. 

Furthermore, higher incidence of familial combined hyperlipidemia, beneficial government initiatives and increase awareness of the treatment are some of the drivers expected to increase the market growth. In the North America region, the United States holds the largest market share. According to Center for Chronic Disease Prevention (CDC), 7% of U.S. children and adolescents ages 6 to 19 have high total cholesterol, therefore a growing number of these diseases in the country is anticipated to stimulate the demand in this region.

Dilated Cardiomyopathy Therapeutic Market

Competitive Landscape

The lipid disorder treatment market is moderately competitive and consists of major players. Some of the companies which are currently domianting the market Pfizer, Inc, Novartis AG, Astrazeneca Plc, Merck & Co., Inc., Sun Pharma, Emcure Pharmaceuticals, Teva Pharmaceuticals, Mylan Pharmaceuticals, Inc., Kowa Pharmaceuticals America, Inc., Glenmark Pharmaceuticals Ltd., Wockhardt Limited.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in Prevalence of Several Lifestyle Diseases

      2. 4.2.2 Rise in the Smoking and Alcohol Consumption

    3. 4.3 Market Restraints

      1. 4.3.1 Side effects of the treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Indication

      1. 5.1.1 Hypercholesterolemia

      2. 5.1.2 Dysbetalipoproteinemia

      3. 5.1.3 Familial Combined Hyperlipidemia

      4. 5.1.4 Others

    2. 5.2 By Distribution Channel

      1. 5.2.1 Hospital Pharmacies

      2. 5.2.2 Retail Pharmacies

      3. 5.2.3 Online Pharmacies

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Pfizer, Inc

      2. 6.1.2 Novartis AG

      3. 6.1.3 Astrazeneca Plc

      4. 6.1.4 Merck & Co. Inc.

      5. 6.1.5 Emcure Pharmaceuticals Ltd.

      6. 6.1.6 Ranbaxy Laboratories Ltd.

      7. 6.1.7 Teva Pharmaceuticals

      8. 6.1.8 Mylan Pharmaceuticals, Inc.

      9. 6.1.9 Kowa Pharmaceuticals America, Inc.

      10. 6.1.10 Glenmark Pharmaceuticals Ltd.

      11. 6.1.11 Sun Pharmaceuticals Industries Ltd.

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Lipid Disorder Treatment Market market is studied from 2018 - 2026.

The Lipid Disorder Treatment Market is growing at a CAGR of 7.8% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Pfizer, Inc, Novartis AG, Astrazeneca Plc, Merck & Co., Inc, Sun Pharma are the major companies operating in Lipid Disorder Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!